MET and lung cancer: Taken together, these data provide support that cooperative enhanced inhibition using dual TKIs against MET and EGFR pathways may be an effective treatment strategy to inhibit lung cancer with intrinsic or acquired T790M-EGFR-mediated TKI resistance.